Apparently, “Clean” science isn’t immune to dirty market realities. Revenues dipped, tariffs tangled trade, and China did what China does best—ruin everyone’s pricing model. The management insists it’s just a temporary headwind, but analysts smelled more than just lab chemicals in those numbers.
Still, a 44% margin in this environment? Not bad for a company that just took a forex slap and a tariff punch. Read on—things get chemically interesting from here.
2. At a Glance
Revenue down 8% YoY: China sneezed, Clean caught the flu.
EBITDA ₹90 cr, down 10% QoQ: Margins refused to fall, though gravity tried.
EBITDA margin 44%: Still flexing those process efficiencies.
PAT ₹65 cr, down 15% QoQ: Forex gremlins stole the last slice of profit.
HALS segment up 25% QoQ: The new favourite child of the lab.
Capex ₹150 cr in H1: Because chemistry isn’t cheap.
3. Management’s Key Commentary
“Revenue declined 8% YoY due to lower sales in established products.” (Translation: The usual moneymakers are on a coffee break. ☕)
“EBITDA margins at 44% remained resilient despite revenue moderation.” (Margins held firm—probably because accountants refused to blink.)
“HALS monthly run rate grew 25% QoQ; we commercialized HALS 2020.” (New molecule, new hope, same optimism.)
“Performance Chemical 1 is undergoing chemical trials; results satisfactory.” (Translation: It hasn’t exploded yet, so we’re calling it a win. 😏)
“Our FMCG client in China backward integrated—volumes may not come back.” (In plain English: the customer ghosted us to DIY their chemistry.)
“Tariff uncertainty in the U.S. causing deferred orders.” (Because nothing says ‘stable business’ like global trade drama.)
“Domestic HALS market share ~50%; expanding to Europe and the U.S.” (Exporting optimism along with stabilizers.)
